News

Apnimed to Participate in the SVB Securities Global Biopharma Conference

Jan 25, 2023

1×1 investor meetings will take place virtually January 31- February 2, 2023

Apnimed Completes Oversubscribed $79.75 Million Series C Extension Financing to Fund Two Planned Phase 3 Trials of AD109, an Oral Medication with the Potential to Be the First Therapy for Direct Treatment of Obstructive Sleep Apnea (OSA)

Jan 3, 2023

Phase 3 Trials Expected to Begin Enrollment in Second Quarter of 2023, Subject to Discussions with the FDA

Apnimed to Present at the Stifel Healthcare Conference

Nov 8, 2022

Apnimed management will participate in the conference taking place November 15-16, 2022 in New York.

Apnimed Announces Positive Topline Results for MARIPOSA Trial of AD109, Drug Candidate with the Potential to be the First Oral Therapy for Obstructive Sleep Apnea (OSA)

Oct 17, 2022

--AD109 Achieved the Primary Endpoint of Reduced Nighttime Airway Obstruction --AD109 Significantly Improved Daytime Impairment Caused by OSA --AD109 Was Well-Tolerated CAMBRIDGE, Mass. October 17, 2022 – Apnimed, a clinical-stage pharmaceutical company focused on...

Apnimed to Participate in the 2nd Annual Needham Biotech Private Company Virtual 1×1 Forum

Oct 12, 2022

CAMBRIDGE, Mass October 12, 2022 – Apnimed, a clinical-stage pharmaceutical company focused on developing oral pharmacologic therapies to treat obstructive sleep apnea (OSA) and related disorders, including its lead candidate AD109, today announced that company...

Apnimed Expands Senior Leadership Team by Appointing John Cronin, MD, Senior Vice President, Clinical Development

Oct 5, 2022

Dr. Cronin has nearly three decades of experience as a leader in clinical sleep medicine and in commercial solutions to sleep disorders.

Apnimed to Participate in the 42nd Annual Canaccord Genuity Global Growth Conference

Aug 4, 2022

The conference will be taking place in Boston, MA on August 8-11, 2022.

Apnimed Granted FDA Fast Track Designation for AD109, a Novel First-in-Class Oral Pharmacologic Combination for the Treatment of Obstructive Sleep Apnea (OSA)

Jun 28, 2022

FDA’s Fast Track designation is intended to facilitate the development and expedite the review of new drugs to treat serious conditions and that fill an unmet medical need.